158 related articles for article (PubMed ID: 18426683)
1. [SDF-1/CXCR4 and multiple myeloma osteolytic bone lesions--review].
Bao L; Huang XJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Apr; 16(2):442-6. PubMed ID: 18426683
[TBL] [Abstract][Full Text] [Related]
2. Targeted disruption of the CXCL12/CXCR4 axis inhibits osteolysis in a murine model of myeloma-associated bone loss.
Diamond P; Labrinidis A; Martin SK; Farrugia AN; Gronthos S; To LB; Fujii N; O'Loughlin PD; Evdokiou A; Zannettino AC
J Bone Miner Res; 2009 Jul; 24(7):1150-61. PubMed ID: 19335218
[TBL] [Abstract][Full Text] [Related]
3. Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients.
Zannettino AC; Farrugia AN; Kortesidis A; Manavis J; To LB; Martin SK; Diamond P; Tamamura H; Lapidot T; Fujii N; Gronthos S
Cancer Res; 2005 Mar; 65(5):1700-9. PubMed ID: 15753365
[TBL] [Abstract][Full Text] [Related]
4. Targeting SDF-1 in multiple myeloma tumor microenvironment.
Bouyssou JM; Ghobrial IM; Roccaro AM
Cancer Lett; 2016 Sep; 380(1):315-8. PubMed ID: 26655999
[TBL] [Abstract][Full Text] [Related]
5. CD138-negative myeloma cells regulate mechanical properties of bone marrow stromal cells through SDF-1/CXCR4/AKT signaling pathway.
Wu D; Guo X; Su J; Chen R; Berenzon D; Guthold M; Bonin K; Zhao W; Zhou X
Biochim Biophys Acta; 2015 Feb; 1853(2):338-47. PubMed ID: 25450979
[TBL] [Abstract][Full Text] [Related]
6. Macrophage Migration Inhibitory Factor (MIF) Supports Homing of Osteoclast Precursors to Peripheral Osteolytic Lesions.
Movila A; Ishii T; Albassam A; Wisitrasameewong W; Howait M; Yamaguchi T; Ruiz-Torruella M; Bahammam L; Nishimura K; Van Dyke T; Kawai T
J Bone Miner Res; 2016 Sep; 31(9):1688-700. PubMed ID: 27082509
[TBL] [Abstract][Full Text] [Related]
7. Gambogic acid inhibits multiple myeloma mediated osteoclastogenesis through suppression of chemokine receptor CXCR4 signaling pathways.
Pandey MK; Kale VP; Song C; Sung SS; Sharma AK; Talamo G; Dovat S; Amin SG
Exp Hematol; 2014 Oct; 42(10):883-96. PubMed ID: 25034231
[TBL] [Abstract][Full Text] [Related]
8. CXCL12/CXCR4 axis in tissue targeting and bone destruction in cancer and multiple myeloma.
Ooi LL; Dunstan CR
J Bone Miner Res; 2009 Jul; 24(7):1147-9. PubMed ID: 19419311
[No Abstract] [Full Text] [Related]
9. CXCR4 is a good survival prognostic indicator in multiple myeloma patients.
Bao L; Lai Y; Liu Y; Qin Y; Zhao X; Lu X; Jiang Q; Lu J; Huang X
Leuk Res; 2013 Sep; 37(9):1083-8. PubMed ID: 23849988
[TBL] [Abstract][Full Text] [Related]
10. [Advance of research on SDF-1/CXCR4 axis and angiogenesis in leukemia--review].
Bao CH; He QT
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Apr; 16(2):447-51. PubMed ID: 18426684
[TBL] [Abstract][Full Text] [Related]
11. Anti-Notch treatment prevents multiple myeloma cells localization to the bone marrow via the chemokine system CXCR4/SDF-1.
Mirandola L; Apicella L; Colombo M; Yu Y; Berta DG; Platonova N; Lazzari E; Lancellotti M; Bulfamante G; Cobos E; Chiriva-Internati M; Chiaramonte R
Leukemia; 2013 Jul; 27(7):1558-66. PubMed ID: 23354012
[TBL] [Abstract][Full Text] [Related]
12. Thalidomide treatment down-regulates SDF-1alpha and CXCR4 expression in multiple myeloma patients.
Oliveira AM; Maria DA; Metzger M; Linardi C; Giorgi RR; Moura F; Martinez GA; Bydlowski SP; Novak EM
Leuk Res; 2009 Jul; 33(7):970-3. PubMed ID: 18976811
[TBL] [Abstract][Full Text] [Related]
13. The CXCR4/SDF-1 chemokine axis: a potential therapeutic target for bone metastases?
Hirbe AC; Morgan EA; Weilbaecher KN
Curr Pharm Des; 2010; 16(11):1284-90. PubMed ID: 20166978
[TBL] [Abstract][Full Text] [Related]
14. Pathophysiology of multiple myeloma bone disease.
Lentzsch S; Ehrlich LA; Roodman GD
Hematol Oncol Clin North Am; 2007 Dec; 21(6):1035-49, viii. PubMed ID: 17996587
[TBL] [Abstract][Full Text] [Related]
15. Update on the pathogenesis of osteolysis in multiple myeloma patients.
Giuliani N; Colla S; Rizzoli V
Acta Biomed; 2004 Dec; 75(3):143-52. PubMed ID: 15796087
[TBL] [Abstract][Full Text] [Related]
16. [The role of SDF-1 and its receptor CXCR4 in tumor metastasis].
Chen H; Tan Y; Cai S; Ma W; Guo Z; Du J; Cai S
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2007 Oct; 24(5):1180-3. PubMed ID: 18027722
[TBL] [Abstract][Full Text] [Related]
17. Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease.
Bam R; Ling W; Khan S; Pennisi A; Venkateshaiah SU; Li X; van Rhee F; Usmani S; Barlogie B; Shaughnessy J; Epstein J; Yaccoby S
Am J Hematol; 2013 Jun; 88(6):463-71. PubMed ID: 23456977
[TBL] [Abstract][Full Text] [Related]
18. Mobilization of myeloma cells involves SDF-1/CXCR4 signaling and downregulation of VLA-4.
Gazitt Y; Akay C
Stem Cells; 2004; 22(1):65-73. PubMed ID: 14688392
[TBL] [Abstract][Full Text] [Related]
19. Myeloma cell-induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast-myeloma hybrid cells.
Andersen TL; Søe K; Sondergaard TE; Plesner T; Delaisse JM
Br J Haematol; 2010 Feb; 148(4):551-61. PubMed ID: 19919653
[TBL] [Abstract][Full Text] [Related]
20. Stromal cell-derived factor-1 binding to its chemokine receptor CXCR4 on precursor cells promotes the chemotactic recruitment, development and survival of human osteoclasts.
Wright LM; Maloney W; Yu X; Kindle L; Collin-Osdoby P; Osdoby P
Bone; 2005 May; 36(5):840-53. PubMed ID: 15794931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
